Skip to main content
ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · IEX Real-Time Price · USD
1.265
-0.095 (-6.99%)
At close: Apr 30, 2024, 3:58 PM
1.320
+0.055 (4.35%)
After-hours: Apr 30, 2024, 6:57 PM EDT

ImmunoPrecise Antibodies Revenue

ImmunoPrecise Antibodies had revenue of $17.67M in the twelve months ending January 31, 2024, with 16.75% growth year-over-year. Revenue in the quarter ending January 31, 2024 was $4.64M with 20.31% year-over-year growth. In the fiscal year ending April 30, 2023, ImmunoPrecise Antibodies had annual revenue of $15.42M with 0.35% growth.

Revenue (ttm)
$17.67M
Revenue Growth
+16.75%
P/S Ratio
1.91
Revenue / Employee
$173,251
Employees
102
Market Cap
33.68M USD

Revenue Chart

* The company reports in CAD currency but revenue data is shown in USD.

History

Fiscal Year End Revenue Change Growth
Apr 30, 202315.42M53.39K0.35%
Apr 30, 202215.37M805.65K5.53%
Apr 30, 202114.56M4.59M46.06%
Apr 30, 20209.97M1.85M22.73%
Apr 30, 20198.12M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
LENSAR 42.16M
electroCore 16.03M
Co-Diagnostics 6.81M
Marker Therapeutics 3.31M
Lucid Diagnostics 2.43M
Revenue Rankings

IPA News

More News